Announcement on Company's Injection of Cetrorelix Acetate Obtaining Drug Registration Approval

Nanjing Hicin Pharmaceutical Co., Ltd.·June 23, 2026·2 pages

✨ AI Summary

Nanjing Haichan Pharmaceutical Co., Ltd. announced it received a drug registration certificate for its injection of cetrorelix acetate from the NMPA. This product is a GnRH antagonist for assisted reproduction. Its approval enriches the company's product line and is expected to positively impact future performance.

Summary generated by AI · Always verify with source document

Full Translation

AI Translation· gemini_document

Stock Code: 300584

Stock Abbreviation: Haichan Pharmaceutical

Announcement No.: 2026-020

Nanjing Haichan Pharmaceutical Co., Ltd.

Announcement on Company's Injection of Cetrorelix Acetate Obtaining Drug Registration Approval

The Company and all members of the Board of Directors guarantee that the information disclosed is true, accurate, and complete, and that there are no false records, misleading statements, or major omissions.

Nanjing Haichan Pharmaceutical Co., Ltd. (hereinafter referred to as the "Company") recently received the "Drug Registration Certificate" approved and issued by the National Medical Products Administration (hereinafter referred to as the "NMPA"). The relevant situation is hereby announced as follows:

I. Basic Information of the Drug

Free accounts get 10 full releases per month. Pro subscribers get unlimited access.